<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2012091310328N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-01-12</date_registration>
      <primary_sponsor>Vise Canceler of Shahid Sadoughi University of Medical Sciences of Yazd, Research and Clinical Cente</primary_sponsor>
      <public_title>The effect of intrauterine human chorionic gonadotropin injection on pregnancy outcomes in infertile patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of intrauterine human chorionic gonadotropin injection before embryo transfer on the implantation and pregnancy rate in infertile patients: A randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-04-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>159</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/10839</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Women who met the inclusion criteria were numbered from 1 to 159 in order of referral. After being explained about the study method and obtaining informed consent two columns of 53 random numbers from 1-159 were produced using statistical soft version Minitab 14 software (Minitab. LLC, 2014. Minitab, Available at: http://www.minitab.com); numbers that were not in these columns were considered as third group. Each lists was randomly assigned to one of the intervention groups A, B and C (control). The simple randomization method was used. Envelopes and codes were assigned for all participants. Group one was marked with A, group two with B and group three with C. A code has been assigned to each envelope and this code was recorded for each participant.</study_design>
      <phase>3</phase>
      <hc_freetext>Infertility.</hc_freetext>
      <i_freetext>Intervention 1: In control group (n=53)  in time of  monitoring  when at least three follicles 18 mm to be seen on ultrasound, 10,000 units HCG will be injected. 36 hours after puncturing oocytes, IVF or ICSI will be performed and 48-72 hours after between 2-3 embryo through   of Cook catheter embryo transfer (ET) will be performed. For luteal phase support progesterone   100 mg intramuscular injection will used . Intervention 2: In  group 1 intervention (n=53)  in time of  monitoring  when at least three follicles 18 mm to be seen on ultrasound, 10,000 units HCG will be injected. 36 hours after puncturing oocytes, IVF or ICSI will be performed. Culture media will  added  to a vial HCG 5000 IU and will be get HCG dilution requirement(500 unit)for intrauterine injection. In the second or third day after the oocyte pickup  ,after inserting a speculum and view the  cervix  in lithotomy position and after  will passed the internal cervical OS , 40 microliter of tissue culture medium containing  500 IU of hCG  through a  soft  catheter( Cook) will injected intrauterine. Approximately 7minutes after  intrauterine HCG injection, between 2-3 embryo through   another  soft catheter( Cook ) embryo transfer (ET) will be performed. For luteal phase support progesterone   100 mg intramuscular injection will used . Intervention 3: In  group 2 intervention (n=53)  in time of  monitoring  when at least three follicles 18 mm to be seen on ultrasound, 10,000 units HCG will be injected. 36 hours after puncturing oocytes, IVF or ICSI will be performed. Culture media will  added  to a vial HCG 5000 IU and will be get HCG dilution requirement(1000 unit)for intrauterine injection. In the second or third day after the oocyte pickup  ,after inserting a speculum and view the  cervix  in lithotomy position and after  will passed the internal cervical OS, 40 microliter of tissue culture medium containing  1000 IU of hCG  through a  soft  catheter( Cook) will injected intrauterine. Approximately 7minutes after  intrauterine HCG injection, between 2-3 embryo through   another  soft catheter( Cook ) embryo transfer (ET) will be performed. For luteal phase support progesterone   100 mg intramuscular injection will used .</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All participant data sets are to be shared

When:
2 months after the result publication

To whom:
Researchers working in academic and scientific institutes, Journal editors and Reviewers

Conditions:
Submission of an official application via the agent that is legally in charge

Where to obtain:
Yazd Reproductive Sciences Institute, Bouali Ave, Yazd, Iran. 983538247085

How to obtain:
Immediately after the Submission of an official application via the agent that is legally in charge (About a month) by sending an email to janati@dums.ac.ir.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Sima Janati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Research and Clinical Center for Infertility, Bouali Ave, Safayeh,Yazd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۹۱۶۸۷۷۳۹۱</zip>
        <telephone>+98 35 1824 7085</telephone>
        <email>janati@dums.ac.ir</email>
        <affiliation>Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences Yazd</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr.Razieh  Dehghani Firouzabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Research and Clinical Center for Infertility, Bouali Ave, Safayeh،  Yazd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۹۱۶۸۷۷۳۹۱</zip>
        <telephone>+98 35 1824 7085</telephone>
        <email>dr-firouzabadi@ssu.ac.ir</email>
        <affiliation>Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences,Yazd</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>female
age in the range of 20-40 years
male factor infertility
unexplained infertility
basal FSH less than 12.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>azoospermia,
presence of uterine myoma
endometriosis
hydrosalpinges
previous IVF/ICSI trials (successful or unsuccessful)
history of endocrine diseases such as diabetes and thyroid dysfunction
previous history of hysterocopic operation due to submoucosal myoma, and intrauterine synechia.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N98.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complications of attempted introduction of embryo in embryo transfe</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In control group (n=53)  in time of  monitoring  when at least three follicles 18 mm to be seen on ultrasound, 10,000 units HCG will be injected. 36 hours after puncturing oocytes, IVF or ICSI will be performed and 48-72 hours after between 2-3 embryo through   of Cook catheter embryo transfer (ET) will be performed. For luteal phase support progesterone   100 mg intramuscular injection will used .</i_keyword>
      <i_keyword>In  group 1 intervention (n=53)  in time of  monitoring  when at least three follicles 18 mm to be seen on ultrasound, 10,000 units HCG will be injected. 36 hours after puncturing oocytes, IVF or ICSI will be performed. Culture media will  added  to a vial HCG 5000 IU and will be get HCG dilution requirement(500 unit)for intrauterine injection. In the second or third day after the oocyte pickup  ,after inserting a speculum and view the  cervix  in lithotomy position and after  will passed the internal cervical OS , 40 microliter of tissue culture medium containing  500 IU of hCG  through a  soft  catheter( Cook) will injected intrauterine. Approximately 7minutes after  intrauterine HCG injection, between 2-3 embryo through   another  soft catheter( Cook ) embryo transfer (ET) will be performed. For luteal phase support progesterone   100 mg intramuscular injection will used .</i_keyword>
      <i_keyword>In  group 2 intervention (n=53)  in time of  monitoring  when at least three follicles 18 mm to be seen on ultrasound, 10,000 units HCG will be injected. 36 hours after puncturing oocytes, IVF or ICSI will be performed. Culture media will  added  to a vial HCG 5000 IU and will be get HCG dilution requirement(1000 unit)for intrauterine injection. In the second or third day after the oocyte pickup  ,after inserting a speculum and view the  cervix  in lithotomy position and after  will passed the internal cervical OS, 40 microliter of tissue culture medium containing  1000 IU of hCG  through a  soft  catheter( Cook) will injected intrauterine. Approximately 7minutes after  intrauterine HCG injection, between 2-3 embryo through   another  soft catheter( Cook ) embryo transfer (ET) will be performed. For luteal phase support progesterone   100 mg intramuscular injection will used .</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Implantation rate. Timepoint: Identified through vaginal or abdominal ultrasound 4-5 wks after the embryo transfer. Method of measurement: Observation of number of gestational  sacs by transvaginal ultrasonography per 100 embryo transfer.</prim_outcome>
      <prim_outcome>Chemical pregnancy. Timepoint: 2 weeks after embryo transfer. Method of measurement: BHCG test.</prim_outcome>
      <prim_outcome>Clinical pregnancy. Timepoint: 4 -5 weeks after embryo transfer. Method of measurement: observation of fetal heart activity by trans vaginal or abdominal  ultrasound.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Abortion. Timepoint: Before the 20th week of pregnancy. Method of measurement: Abortion product observation (placenta and fetus residual).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vise Canceler of Shahid Sadoughi University of Medical Sciences of Yazd, Research and Clinical Cente</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-03-15</approval_date>
        <contact_name>Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences,Yazd</contact_name>
        <contact_address>Research and Clinical Center for Infertility, Bouali Ave, Safayeh,  Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
